IL89276A - A preparation containing human relaxin - Google Patents

A preparation containing human relaxin

Info

Publication number: IL89276A
Authority: IL; Israel
Prior art keywords: relaxin; composition; buffer; formulation; gel
Prior art date: 1988-02-26

Application number

IL8927689A

Other languages

English (en)

Hebrew (he)

Other versions

IL89276A0 (en

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-26

Filing date

1989-02-14

Publication date

1994-06-24

1989-02-14 Application filed by Genentech Inc filed Critical Genentech Inc

1989-02-14 Priority to IL108658A priority Critical patent/IL108658A/en

1989-09-10 Publication of IL89276A0 publication Critical patent/IL89276A0/xx

1994-06-24 Publication of IL89276A publication Critical patent/IL89276A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 150
BJRCFZKVYNDCJE-WBSNEMHCSA-N 99489-95-9 Chemical compound C([C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N2)[C@@H](C)CC)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC1=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1=CC=C(O)C=C1 BJRCFZKVYNDCJE-WBSNEMHCSA-N 0.000 title claims abstract description 54
238000009472 formulation Methods 0.000 title description 83
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 75
239000000872 buffer Substances 0.000 claims abstract description 39
239000011780 sodium chloride Substances 0.000 claims abstract description 38
239000007979 citrate buffer Substances 0.000 claims abstract description 24
239000003795 chemical substances by application Substances 0.000 claims abstract description 13
230000032696 parturition Effects 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 49
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 34
235000011187 glycerol Nutrition 0.000 claims description 17
239000007788 liquid Substances 0.000 claims description 17
-1 alkaline earth metal salt Chemical class 0.000 claims description 14
230000035935 pregnancy Effects 0.000 claims description 12
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
229930195725 Mannitol Natural products 0.000 claims description 10
239000000594 mannitol Substances 0.000 claims description 10
235000010355 mannitol Nutrition 0.000 claims description 10
150000005846 sugar alcohols Chemical class 0.000 claims description 8
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 5
239000008351 acetate buffer Substances 0.000 claims description 5
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
150000007524 organic acids Chemical group 0.000 claims description 4
230000037195 reproductive physiology Effects 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
239000004386 Erythritol Substances 0.000 claims description 2
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
239000007853 buffer solution Substances 0.000 claims description 2
235000019414 erythritol Nutrition 0.000 claims description 2
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
229940009714 erythritol Drugs 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
235000010356 sorbitol Nutrition 0.000 claims description 2
239000000811 xylitol Substances 0.000 claims description 2
235000010447 xylitol Nutrition 0.000 claims description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
229960002675 xylitol Drugs 0.000 claims description 2
150000001340 alkali metals Chemical group 0.000 claims 2
229910001508 alkali metal halide Inorganic materials 0.000 claims 1
229910001615 alkaline earth metal halide Inorganic materials 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229920001451 polypropylene glycol Polymers 0.000 claims 1
230000002378 acidificating effect Effects 0.000 abstract description 4
239000003381 stabilizer Substances 0.000 abstract description 2
206010036595 Premature delivery Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
108090000103 Relaxin Proteins 0.000 description 225
102000003743 Relaxin Human genes 0.000 description 224
239000000499 gel Substances 0.000 description 69
108090000623 proteins and genes Proteins 0.000 description 35
238000006731 degradation reaction Methods 0.000 description 32
230000015556 catabolic process Effects 0.000 description 31
238000004007 reversed phase HPLC Methods 0.000 description 30
102000004169 proteins and genes Human genes 0.000 description 28
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
229920000609 methyl cellulose Polymers 0.000 description 24
239000001923 methylcellulose Substances 0.000 description 24
235000010981 methylcellulose Nutrition 0.000 description 23
150000001413 amino acids Chemical class 0.000 description 21
238000004128 high performance liquid chromatography Methods 0.000 description 21
239000000523 sample Substances 0.000 description 21
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
210000002966 serum Anatomy 0.000 description 20
238000003556 assay Methods 0.000 description 19
239000000243 solution Substances 0.000 description 19
241000282414 Homo sapiens Species 0.000 description 18
238000000034 method Methods 0.000 description 18
230000000699 topical effect Effects 0.000 description 18
210000004027 cell Anatomy 0.000 description 17
210000003679 cervix uteri Anatomy 0.000 description 16
230000000694 effects Effects 0.000 description 16
241000283973 Oryctolagus cuniculus Species 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
238000002965 ELISA Methods 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
238000003860 storage Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
235000010323 ascorbic acid Nutrition 0.000 description 10
239000011668 ascorbic acid Substances 0.000 description 10
229960005070 ascorbic acid Drugs 0.000 description 10
239000012537 formulation buffer Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
229920003091 Methocel™ Polymers 0.000 description 9
230000008033 biological extinction Effects 0.000 description 9
210000004246 corpus luteum Anatomy 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
230000006870 function Effects 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
239000011777 magnesium Substances 0.000 description 8
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
238000012286 ELISA Assay Methods 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
229920002678 cellulose Polymers 0.000 description 7
235000010980 cellulose Nutrition 0.000 description 7
229940095074 cyclic amp Drugs 0.000 description 7
238000000502 dialysis Methods 0.000 description 7
238000004108 freeze drying Methods 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000012901 Milli-Q water Substances 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
239000011521 glass Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
229920001282 polysaccharide Polymers 0.000 description 5
239000005017 polysaccharide Substances 0.000 description 5
150000004804 polysaccharides Chemical class 0.000 description 5
239000000843 powder Substances 0.000 description 5
210000004061 pubic symphysis Anatomy 0.000 description 5
230000005070 ripening Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000001179 sorption measurement Methods 0.000 description 5
239000004471 Glycine Substances 0.000 description 4
238000010268 HPLC based assay Methods 0.000 description 4
101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
238000013019 agitation Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000001793 charged compounds Chemical class 0.000 description 4
238000002983 circular dichroism Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 4
125000001033 ether group Chemical class 0.000 description 4
230000012447 hatching Effects 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000012669 liquid formulation Substances 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
108010087851 prorelaxin Proteins 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000000870 ultraviolet spectroscopy Methods 0.000 description 4
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
238000013103 analytical ultracentrifugation Methods 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000011888 foil Substances 0.000 description 3
230000002962 histologic effect Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000011068 loading method Methods 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000007539 photo-oxidation reaction Methods 0.000 description 3
108010090955 preprorelaxin Proteins 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000047 product Substances 0.000 description 3
230000017854 proteolysis Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
238000004062 sedimentation Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
241000894007 species Species 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
108010075254 C-Peptide Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
101500024627 Homo sapiens Relaxin A chain Proteins 0.000 description 2
101500024645 Homo sapiens Relaxin A chain Proteins 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
208000006399 Premature Obstetric Labor Diseases 0.000 description 2
206010036600 Premature labour Diseases 0.000 description 2
102100034949 Prorelaxin H2 Human genes 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000004847 absorption spectroscopy Methods 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
230000004075 alteration Effects 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000001142 circular dichroism spectrum Methods 0.000 description 2
229960004106 citric acid Drugs 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000002219 extraembryonic membrane Anatomy 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000013022 formulation composition Substances 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
239000012520 frozen sample Substances 0.000 description 2
102000049116 human RLN2 Human genes 0.000 description 2
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
210000003041 ligament Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
208000026440 premature labor Diseases 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
210000005000 reproductive tract Anatomy 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
229960000999 sodium citrate dihydrate Drugs 0.000 description 2
UPMFZISCCZSDND-JJKGCWMISA-M sodium gluconate Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UPMFZISCCZSDND-JJKGCWMISA-M 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000019100 sperm motility Effects 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000008362 succinate buffer Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000010257 thawing Methods 0.000 description 2
XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
NAQWICRLNQSPPW-UHFFFAOYSA-N 1,2,3,4-tetrachloronaphthalene Chemical compound C1=CC=CC2=C(Cl)C(Cl)=C(Cl)C(Cl)=C21 NAQWICRLNQSPPW-UHFFFAOYSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
239000008001 CAPS buffer Substances 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000003670 Carboxypeptidase B Human genes 0.000 description 1
108090000087 Carboxypeptidase B Proteins 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
229920001503 Glucan Polymers 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000569 Gum karaya Polymers 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
101500024628 Homo sapiens Relaxin B chain Proteins 0.000 description 1
101500024640 Homo sapiens Relaxin B chain Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000014429 Insulin-like growth factor Human genes 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
229920000057 Mannan Polymers 0.000 description 1
229920003108 Methocel™ A4M Polymers 0.000 description 1
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000057361 Pseudogenes Human genes 0.000 description 1
108091008109 Pseudogenes Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000251778 Squalus acanthias Species 0.000 description 1
241000934878 Sterculia Species 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
KBAYQFWFCOOCIC-GNVSMLMZSA-N [(1s,4ar,4bs,7s,8ar,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,7,8,8a,9,10,10a-dodecahydrophenanthren-1-yl]methanol Chemical compound OC[C@@]1(C)CCC[C@]2(C)[C@H]3CC[C@H](C(C)C)C[C@H]3CC[C@H]21 KBAYQFWFCOOCIC-GNVSMLMZSA-N 0.000 description 1
GZLGNNHEHXBCBI-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O GZLGNNHEHXBCBI-UHFFFAOYSA-L 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229940099352 cholate Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960002303 citric acid monohydrate Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
KNKDZWFHOIKECV-UHFFFAOYSA-L dipotassium 2,3,4-trihydroxy-4-oxobutanoate Chemical compound [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O KNKDZWFHOIKECV-UHFFFAOYSA-L 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
238000010265 fast atom bombardment Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
229960004675 fusidic acid Drugs 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000009027 insemination Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
235000010494 karaya gum Nutrition 0.000 description 1
239000000231 karaya gum Substances 0.000 description 1
229940039371 karaya gum Drugs 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000004807 localization Effects 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
230000029860 luteolysis Effects 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
229910001623 magnesium bromide Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
210000000754 myometrium Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000004224 potassium gluconate Substances 0.000 description 1
229960003189 potassium gluconate Drugs 0.000 description 1
LCPMNMXCIHBTEX-UHFFFAOYSA-M potassium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [K+].CC(O)C(O)=O.CC(O)C([O-])=O LCPMNMXCIHBTEX-UHFFFAOYSA-M 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000010453 quartz Substances 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
239000000176 sodium gluconate Substances 0.000 description 1
229940005574 sodium gluconate Drugs 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
LLVQEXSQFBTIRD-UHFFFAOYSA-M sodium;2,3,4-trihydroxy-4-oxobutanoate;hydrate Chemical compound O.[Na+].OC(=O)C(O)C(O)C([O-])=O LLVQEXSQFBTIRD-UHFFFAOYSA-M 0.000 description 1
KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 1
VDZDAHYKYRVHJR-UHFFFAOYSA-M sodium;2-hydroxypropanoate;hydrate Chemical compound [OH-].[Na+].CC(O)C(O)=O VDZDAHYKYRVHJR-UHFFFAOYSA-M 0.000 description 1
OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 1
VBGUQBPWJMPQBI-UHFFFAOYSA-M sodium;butanedioic acid;4-hydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)CCC(O)=O.OC(=O)CCC([O-])=O VBGUQBPWJMPQBI-UHFFFAOYSA-M 0.000 description 1
JISIBLCXFLGVJX-UHFFFAOYSA-M sodium;butanedioic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CCC(O)=O JISIBLCXFLGVJX-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
238000013519 translation Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
239000011123 type I (borosilicate glass) Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
229920001221 xylan Polymers 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Electrotherapy Devices (AREA)
Materials For Medical Uses (AREA)
Control Of Motors That Do Not Use Commutators (AREA)
Steroid Compounds (AREA)

IL8927689A 1988-02-26 1989-02-14 A preparation containing human relaxin IL89276A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL108658A IL108658A (en)	1988-02-26	1989-02-14	Human relaxin pharmaceutical gel compositions

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16079788A	1988-02-26	1988-02-26
US30377989A	1989-01-27	1989-01-27

Publications (2)

Publication Number	Publication Date
IL89276A0 IL89276A0 (en)	1989-09-10
IL89276A true IL89276A (en)	1994-06-24

Family

ID=26857232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8927689A IL89276A (en)	1988-02-26	1989-02-14	A preparation containing human relaxin

Country Status (14)

Country	Link
US (2)	US5451572A (de)
EP (1)	EP0407401B1 (de)
JP (1)	JP2815649B2 (de)
CN (1)	CN1052655C (de)
AT (1)	ATE88352T1 (de)
AU (1)	AU626840B2 (de)
CA (1)	CA1336403C (de)
DE (1)	DE68906153T2 (de)
ES (1)	ES2013394A6 (de)
IE (1)	IE63208B1 (de)
IL (1)	IL89276A (de)
NZ (1)	NZ228012A (de)
PT (1)	PT89835B (de)
WO (1)	WO1989007945A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5478807A (en) *	1991-08-19	1995-12-26	Genentech, Inc.	Use of relaxin in the treatment of bradycardia
US5166191A (en) *	1991-08-19	1992-11-24	Genentech, Inc.	Use of relaxin in cardiovascular therapy
WO1993009436A1 (en) *	1991-10-28	1993-05-13	Board Of Regents, The University Of Texas System	A method for detecting a differentiation marker in normal and carcinoma cells and in biological samples and body fluid
US5192743A (en) *	1992-01-16	1993-03-09	Genentech, Inc.	Reconstitutable lyophilized protein formulation
US5830848A (en) *	1992-10-09	1998-11-03	The Regents Of The University Of California	Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
FI971533A7 (fi) *	1994-10-13	1997-04-11	Wakamoto Pharma Co Ltd	Lyofilisoituja farmaseuttisia valmisteita, jotka kykenevät muodostamaa n vesipitoisen lääkekoostumuksen, jolla on palautuvan, lämpökovettuvan geelittymisen ominaisuus
US5811395A (en) *	1995-06-07	1998-09-22	Medical University Of South Carolina	Relaxin analogs and derivatives methods and uses thereof
ES2187667T3 (es)	1995-08-15	2003-06-16	Connetics Corp	Uso de relaxina para estimular angiogenesis.
US5612051A (en) *	1995-11-17	1997-03-18	Yue; Samuel K.	Method of treating involuntary muscle dysfunction with relaxin hormone
EP0852951A1 (de)	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US5994148A (en)	1997-06-23	1999-11-30	The Regents Of University Of California	Method of predicting and enhancing success of IVF/ET pregnancy
US6251863B1 (en)	1998-09-08	2001-06-26	Samuel K. Yue	Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
ES2242439T3 (es) *	1998-12-18	2005-11-01	Palladin Healthcare International Ltd	Composicion para el tratamiento de quemaduras.
ATE362770T1 (de) *	2000-02-09	2007-06-15	Bas Medical Inc	Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
US20050032683A1 (en) *	2000-10-04	2005-02-10	Amento Edward P.	Methods of modulating apoptosis by administration of relaxin agonists or antagonists
WO2002098445A1 (fr) *	2001-05-30	2002-12-12	Chugai Seiyaku Kabushiki Kaisha	Preparation de proteines
US20100134794A1 (en) *	2004-02-05	2010-06-03	Medpro Holdings, Llc	Analyzer for determining the concentration, potency and purity of pharmaceutical compounds
US7660678B2 (en) *	2004-02-05	2010-02-09	Medpro Holdings, Llc	On-site method of providing analysis of potency and purity of pharmaceutical compounds
US7878978B2 (en)	2004-03-18	2011-02-01	University Of Pittsburgh- Of The Commonwealth System Of Higher Education	Use of relaxin to increase arterial compliance
AU2005247332A1 (en) *	2004-04-30	2005-12-08	Corthera, Inc.	Methods and compositions for control of fetal growth via modulation of relaxin
US7597884B2 (en)	2004-08-09	2009-10-06	Alios Biopharma, Inc.	Hyperglycosylated polypeptide variants and methods of use
MX2007001589A (es) *	2004-08-09	2007-08-02	Alios Biopharma Inc	Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US20060052304A1 (en) *	2004-09-02	2006-03-09	Bas Medical, Inc.	Method for remodeling bone and related sutures
US20080241260A1 (en) *	2005-09-28	2008-10-02	Padma Venkitachalam Devarajan	Compositions for Enhanced Absorption of Biologically Active Agents
RU2501573C2 (ru) *	2008-05-16	2013-12-20	Кортера, Инк.	Способ предупреждения преждевременных родов
US20100041603A1 (en) *	2008-05-16	2010-02-18	Corthera, Inc.	Method of Promoting Wound Healing
EP2405933A1 (de) *	2009-03-13	2012-01-18	Medtronic, Inc	Verfahren zur behandlung von herzinsuffizienz
US20130053318A1 (en)	2010-03-10	2013-02-28	Parry Laura	Modulating aquaporins with relaxin
SI2605789T1 (sl)	2010-08-17	2019-10-30	Ambrx Inc	Modificirani polipeptidi relaksina in njihova uporaba
CN102133200B (zh) *	2011-03-16	2012-07-25	济南环肽医药科技有限公司	一种人类松弛素-2 Relaxin的注射用冻干粉制剂
US9393288B2 (en)	2012-05-29	2016-07-19	The University Of Vermont And State Agricultural College	Methods of treating diseases associated with PPARγ
CN103768584A (zh) *	2014-02-10	2014-05-07	济南环肽医药科技有限公司	一种松弛肽注射液
CN104922661B (zh) *	2014-03-20	2018-08-24	深圳翰宇药业股份有限公司	一种含有serelaxin的药物组合物及其制备方法
WO2016059593A1 (en) *	2014-10-16	2016-04-21	Piramal Enterprises Limited	Stable injectable composition of protein drugs and process for its preparation
CN107007822A (zh) *	2016-01-27	2017-08-04	江苏恒瑞医药股份有限公司	一种含有重组人松弛素‑2类似物的药物组合物及其制备方法
PE20191716A1 (es)	2017-02-08	2019-12-05	Bristol Myers Squibb Co	Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
EP3600233A4 (de) *	2017-03-26	2020-10-21	Stafford, Vivi, Robyn	Verfahren zur behandlung von hautleiden der augenlider
WO2025056188A1 (en) *	2023-09-15	2025-03-20	Relaxera Pharmazeutische Gmbh & Co. Kg	Relaxin medication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2964448A (en) *	1959-01-27	1960-12-13	Anschel Joachim	Relaxin composition and process for preparing same
US3003117A (en) *	1959-09-29	1961-10-03	Gen Frecision Inc	Coincident frequency tracker
US3962416A (en) *	1971-01-25	1976-06-08	Sol Katzen	Preserved nutrients and products
DE3064888D1 (en) *	1979-04-30	1983-10-27	Hoechst Ag	Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4267101A (en) *	1980-02-01	1981-05-12	Serono Laboratories Inc.	Process for obtaining human relaxin from fetal membranes
EP0080879B1 (de) *	1981-11-28	1986-10-01	Sunstar Kabushiki Kaisha	Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
DK171827B1 (da) *	1982-08-12	1997-06-23	Florey Howard Inst	Dobbeltstrenget DNA-fragment, der koder for human-H1-præprorelaxin, human-H1-prorelaxin eller A- og B-kæderne i human-H1-relaxin, samt DNA-transfervektor, der indeholder en cDNA-deoxynukleotidsekvens, som svarer til et sådant DNA-fragment, celle transformeret med en sådan DNA-transfervektor, og fremgangsmåde til fremstilling af human-H1-prorelaxin eller -H1-relaxin ved dyrkning af en sådan celle
DE3236267A1 (de) *	1982-09-30	1984-04-05	Serono Pharmazeutische Präparate GmbH, 7800 Freiburg	Verfahren zur herstellung von relaxin und verfahren zur hochreinigung von relaxin
DE3236264A1 (de) *	1982-09-30	1984-04-05	Serono Pharmazeutische Präparate GmbH, 7800 Freiburg	Verfahren zur gewinnung von relaxin
IL70414A (en) *	1982-12-13	1991-06-10	Florey Howard Inst	Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
CH661662A5 (en) *	1984-04-16	1987-08-14	Georg L Prof Dr Floersheim	Product for the treatment of the skin and of the connective tissue
US4605555A (en) *	1984-09-20	1986-08-12	Sun Star Kabushiki Kaisha	Composition and method for treating keratosic disorder of skin and mucosa
US4806343A (en) *	1986-03-13	1989-02-21	University Of Southwestern Louisiana	Cryogenic protectant for proteins
AU612594B2 (en) *	1986-09-12	1991-07-18	Genentech Inc.	Human prorelaxin
US4717717A (en) *	1986-11-05	1988-01-05	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor

1989
- 1989-02-08 EP EP89902688A patent/EP0407401B1/de not_active Expired - Lifetime
- 1989-02-08 WO PCT/US1989/000502 patent/WO1989007945A1/en not_active Ceased
- 1989-02-08 JP JP1502501A patent/JP2815649B2/ja not_active Expired - Fee Related
- 1989-02-08 DE DE89902688T patent/DE68906153T2/de not_active Expired - Fee Related
- 1989-02-08 AT AT89902688T patent/ATE88352T1/de not_active IP Right Cessation
- 1989-02-08 AU AU31833/89A patent/AU626840B2/en not_active Ceased
- 1989-02-13 IE IE45289A patent/IE63208B1/en not_active IP Right Cessation
- 1989-02-14 IL IL8927689A patent/IL89276A/en unknown
- 1989-02-16 NZ NZ228012A patent/NZ228012A/en unknown
- 1989-02-23 CA CA000591933A patent/CA1336403C/en not_active Expired - Lifetime
- 1989-02-24 PT PT89835A patent/PT89835B/pt not_active IP Right Cessation
- 1989-02-24 ES ES8900688A patent/ES2013394A6/es not_active Expired - Lifetime
- 1989-02-25 CN CN89100947A patent/CN1052655C/zh not_active Expired - Fee Related
1993
- 1993-04-20 US US08/050,745 patent/US5451572A/en not_active Expired - Lifetime
1995
- 1995-06-06 US US08/471,920 patent/US5945402A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE68906153D1 (de)	1993-05-27
CA1336403C (en)	1995-07-25
IE890452L (en)	1989-08-26
IL89276A0 (en)	1989-09-10
US5945402A (en)	1999-08-31
DE68906153T2 (de)	1993-10-28
EP0407401B1 (de)	1993-04-21
PT89835B (pt)	1994-01-31
JP2815649B2 (ja)	1998-10-27
JPH03502794A (ja)	1991-06-27
NZ228012A (en)	1991-07-26
ES2013394A6 (es)	1990-05-01
PT89835A (pt)	1989-10-04
AU3183389A (en)	1989-09-22
IE63208B1 (en)	1995-04-05
CN1035619A (zh)	1989-09-20
US5451572A (en)	1995-09-19
CN1052655C (zh)	2000-05-24
WO1989007945A1 (en)	1989-09-08
AU626840B2 (en)	1992-08-13
ATE88352T1 (de)	1993-05-15
EP0407401A1 (de)	1991-01-16

Publication	Publication Date	Title
CA1336403C (en)	1995-07-25	Human relaxin formulation
KR101662631B1 (ko)	2016-10-05	Ｆｓｈ의 액체 포뮬레이션
JPH04217630A (ja)	1992-08-07	安定化されたゴナドトロピンを含有する調製品
CA2348167C (en)	2012-01-10	Pharmaceutical administration form for peptides, process for its preparation, and use
KR101105486B1 (ko)	2012-01-13	Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
KR101024511B1 (ko)	2011-03-31	올리고펩티드 및 에테르화된 시클로덱스트린을 포함하는액상 제제
JP4871124B2 (ja)	2012-02-08	凍結乾燥ｆｓｈ／ｌｈ製剤
KR100245534B1 (ko)	2000-03-02	피브릴화된 칼시토닌을 포함하는 약제학적 조성물, 이의 제조방법 및 칼시토닌 피브릴의 분산액
JP3822383B2 (ja)	2006-09-20	可溶性トロンボモジュリン含有組成物
IL108658A (en)	1998-03-10	Human relaxin pharmaceutical gel compositions
US20090029911A1 (en)	2009-01-29	Liquid Human Growth Hormone Formulation Containing Polyethylene Glycol
WO1995002411A1 (en)	1995-01-26	Stabilised polypeptide growth factor formulation at low ph
JP2005060377A (ja)	2005-03-10	インターロイキン−１１含有凍結乾燥製剤
WO2007034509A2 (en)	2007-03-29	Recombinant granulocyte-colony stimulating factor formulation and process
HK1149494B (en)	2012-05-25	Liquid formulation of fsh

Legal Events

Date	Code	Title
1999-07-14	KB	Patent renewed
2003-04-10	KB	Patent renewed
2007-05-21	KB	Patent renewed